Stock BIOBLAST PHARMA LTD
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Other languages Bioblast Pharma Ltd Nasdaq

Equities

IL0011319527

Other languages

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Enlivex Therapeutics Says First Patient Dosed in Phase 1/2 Thumb Osteoarthritis Trial
Enlivex Therapeutics Ltd. Announces the Dosing of the First Patient in a Randomized, Placebo-Controlled Phase I/II Trial Evaluating AllocetraTM in up to 46 Patients with Thumb Osteoarthritis
Enlivex Announces Positive Interim Data Readout from a Phase I/II Trial Evaluating Allocetra in End-Stage Knee Osteoarthritis
Enlivex Therapeutics Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
Enlivex Receives Regulatory Authorization for the Initiation of a Placebo-Controlled Phase I/II Trial Evaluating Allocetra in Up To 46 Patients with Thumb Osteoarthritis
Enlivex Therapeutics to Launch Registered Direct Offering; Shares Fall
Enlivex Therapeutics Ltd. Announces Dosing of First Two Patients in its Randomized, Controlled Phase I/II Trial Evaluating Allocetra? in Patients with Knee Osteoarthritis
Enlivex Therapeutics Ltd Announces Authorization from the Danish Regulatory Agency for the Company's Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis
Sector Update: Health Care Stocks Softer Late Afternoon
Sector Update: Health Care
Enlivex Therapeutics Shares Fall After Topline Data from Sepsis Treatment Study
Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra? in Patients with Sepsis
Enlivex Therapeutics Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
Enlivex Announces Issuance of New U.S. Patent Covering Allocetra Cells and Their Manufacturing Method
Enlivex Receives IMOH Regulatory Authorization for the Initiation of a Multi-Country, Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Up To 160 Patients with Moderate to Severe Knee Osteoarthritis
Enlivex Therapeutics Ltd.'s Equity Buyback Plan Extended till June 30, 2024.
Top Midday Gainers
Enlivex Therapeutics Ltd. Announces Completion of Enrollment of its Phase II Trial Evaluating Allocetra in Patients with Sepsis
Enlivex Therapeutics Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Enlivex Therapeutics Ltd. announces an Equity Buyback for $1.5 million worth of its shares.
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ENLV Stock
  4. Stock
  5. News Bioblast Pharma Ltd
  6. Other languages